Literature DB >> 23870302

Ten-year results of a randomized controlled trial comparing 0.02% mitomycin C and limbal conjunctival autograft in pterygium surgery.

Alvin L Young1, Mary Ho2, Vishal Jhanji2, Lulu Lu Cheng2.   

Abstract

OBJECTIVE: To compare the long-term outcome of pterygium surgery and the long-term effect on endothelial counts after mitomycin C (MMC) or limbal conjunctival autograft (LCAU) in pterygium surgery.
DESIGN: We performed a 10-year follow-up study of a randomized controlled trial. PARTICIPANTS: A total of 115 eyes of 114 patients with primary pterygium were treated with intraoperative MMC (n = 63) or LCAU transplants (n = 52). A total of 76 patients completed the current 10-year long-term follow-up (47 in the MMC group, 29 in the LCAU group).
METHODS: This is a follow-up study of a randomized controlled trial of a cohort of 114 patients in 2 groups that was performed at the Prince of Wales Hospital 10 years ago: group 1, intraoperative 0.02% MMC for 5 minutes; group 2, LCAU. Consecutive patients enrolled in the original study (recruitment began in February 2001) were invited back for a detailed clinical examination to document the long-term outcome of both surgical groups. MAIN OUTCOME MEASURES: The main outcome measures included the recurrence rate, residual conjunctival bed status, complications, and corneal endothelial cell density (ECD) differences.
RESULTS: A total of 115 eyes of 114 patients were enrolled and randomized in our previous study. For the current study, 76 of the 114 patients (47 in the MMC group, 29 in the LCAU group) were contacted, whereas 18 patients were lost to follow-up and 20 patients had died. The mean follow-up period was 138 ± 2 months in the MMC group and 137 ± 2 months in the LCAU group. Twelve of 47 patients (25.5%) in the original MMC group and 2 of 29 patients (6.9%) in the LCAU group had recurrent pterygium (P = 0.021). The mean ECD was 2,39 2 ± 342 cells/mm(2) in the MMC group and 2,390 ± 388 cells/mm(2) in the LCAU group (P = 0.978). There was no significant difference in the ECD between the operated eyes and the fellow eyes in both groups (P = 0.926 MMC, P = 0.468 LCAU). No other significant ocular complications were observed in either group at the 10-year postoperative follow-up.
CONCLUSIONS: Limbal conjunctival autograft was more effective than intraoperative MMC in minimizing pterygium recurrence at the 10-year follow-up. Treatment with intraoperative MMC was not associated with long-term corneal endothelial cell loss.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23870302     DOI: 10.1016/j.ophtha.2013.05.033

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  12 in total

Review 1.  Developments and current approaches in the treatment of pterygium.

Authors:  Dilek Hacıoğlu; Hidayet Erdöl
Journal:  Int Ophthalmol       Date:  2016-09-23       Impact factor: 2.031

2.  Bibliometric analysis and mapping knowledge domain of pterygium: 2000-2019.

Authors:  Yu-Chi Wang; Fang-Kun Zhao; Qian Liu; Zi-Yan Yu; Jing Wang; Jin-Song Zhang
Journal:  Int J Ophthalmol       Date:  2021-06-18       Impact factor: 1.779

Review 3.  Mitomycin C in pterygium treatment.

Authors:  Thiago Gonçalves Dos Santos Martins; Ana Luiza Fontes de Azevedo Costa; Milton Ruiz Alves; Roger Chammas; Paulo Schor
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

4.  Limbal conjunctival versus amniotic membrane in the intraoperative application of mitomycin C for recurrent pterygium: a randomized controlled trial.

Authors:  Rongxin Chen; Guofu Huang; Shu Liu; Wenfang Ma; Xiaofang Yin; Shiyou Zhou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-20       Impact factor: 3.117

5.  Clinical analysis of risk factors contributing to recurrence of pterygium after excision and graft surgery.

Authors:  Sang Won Ha; Joon Ho Park; Im Hee Shin; Hong Kyun Kim
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

6.  In vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts.

Authors:  Magda Massae Hata Viveiros; Fabiano Yutaka Kakizaki; Laura Almeida Hércules; Carlos Roberto Padovani; João Manuel Grisi Candeias; Silvana Artioli Schellini
Journal:  Int Ophthalmol       Date:  2015-08-11       Impact factor: 2.031

7.  Fifteen-year results of a randomized controlled trial comparing 0.02% mitomycin C, limbal conjunctival autograft, and combined mitomycin C with limbal conjunctival autograft in recurrent pterygium surgery.

Authors:  Ka Wai Kam; Alvin L Young
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-10-24       Impact factor: 3.117

8.  [Outcome of pterygium excision after various surgical techniques-is excision with simple conjunctival closure still lege artis?]

Authors:  K Eisenmann; F Zeman; H Helbig; M-A Gamulescu; T Barth
Journal:  Ophthalmologe       Date:  2020-04       Impact factor: 1.059

9.  Bare sclera resection followed by mitomycin C and/or autograft limbus conjunctiva in the surgery for pterygium: a Meta-analysis.

Authors:  Tan Long; Zhi Li
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

10.  Twelve-Year Outcomes of Pterygium Excision with Conjunctival Autograft versus Intraoperative Mitomycin C in Double-Head Pterygium Surgery.

Authors:  Tommy C Y Chan; Raymond L M Wong; Emmy Y M Li; Hunter K L Yuen; Emily F Y Yeung; Vishal Jhanji; Ian Y H Wong
Journal:  J Ophthalmol       Date:  2015-02-25       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.